Medications such as semaglutide and tirzepatide have changed the conversation around obesity. For many people, they work remarkably well. They can reduce appetite, produce substantial weight loss, improve blood sugar, and—in the right patients—reduce important health risks.
But there is another part of the conversation that deserves just as much attention: What happens when the medication stops?
This is not a theoretical question. Cost, insurance coverage, side effects, medication shortages, personal preference, and changing health circumstances can all lead people to discontinue treatment. And we now have increasingly good data about what happens afterward.
The answer is uncomfortable, but important: for many people, a meaningful portion of the benefit begins to reverse.
A 2025 systematic review and meta-analysis published in eClinicalMedicine pooled 18 randomized controlled trials involving 3,771 participants who were followed for at least 12 weeks after stopping a GLP-1–based medication. The median treatment period was 52 weeks, and post-treatment follow-up ranged from 12 to 52 weeks.
Among participants with overweight or obesity, after stopping treatment the average changes were:
The changes did not stop there. LDL cholesterol, total cholesterol, triglycerides, and VLDL also increased significantly after discontinuation.
In participants with type 2 diabetes, the average weight regain was smaller—2.03 kg (4.5 lb)—but HbA1c increased by an average of 0.65 percentage points after treatment ended.
These are averages, not predictions for any one individual. The trials were also highly variable for many outcomes. But the overall direction of the evidence is strikingly consistent: when the medication is removed, some of the metabolic improvements frequently begin moving back toward baseline.
This may be the most important number in the entire paper.
In obesity trials with 26 weeks or less of follow-up after discontinuation, participants regained an average of 2.51 kg (5.5 lb).
When follow-up extended beyond 26 weeks, average regain climbed to 7.31 kg (16.1 lb).
Waist circumference followed the same pattern: +1.60 cm with shorter follow-up versus +4.78 cm with longer follow-up.
This matters because a few weeks after stopping a medication may give a misleading picture of long-term maintenance. Rebound can continue over time.
The evidence does not tell us that every patient will regain all the weight they lost, nor does it tell us exactly what will happen several years after discontinuation—the trials in this analysis followed people for no more than 52 weeks after stopping. But within the period we can actually measure, longer follow-up generally revealed greater regain.
One of the trials included in the review, the STEP 1 extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022), gives us an especially clear example.
Participants treated with semaglutide 2.4 mg plus a structured lifestyle intervention had lost an average of 17.3% of their body weight by week 68. Both the semaglutide and the lifestyle intervention were then stopped. One year later, participants had regained 11.6 percentage points of body weight.
Put plainly: about two-thirds of the weight they had lost came back within one year.
The trial also found that many of the cardiometabolic improvements seen during treatment moved back toward baseline after semaglutide was stopped.
The review also highlighted the SURMOUNT-4 trial. After tirzepatide was discontinued, more than 50% of the weight participants had lost rebounded over the following 52 weeks.
That finding reinforces the broader pattern seen across the review: the benefits of these medications can be substantial, but maintaining those benefits after the medication is stopped can be difficult.
That conclusion would go beyond the evidence.
GLP-1–based medications affect appetite, satiety, gastric emptying, insulin signaling, and other physiological systems while they are being taken. When the medication is withdrawn, those pharmacologic effects do not simply remain behind forever.
Obesity is also not a failure of willpower. Body weight is regulated by biology as well as behavior, environment, sleep, medications, genetics, food availability, activity, and many other factors. Weight regain after stopping an effective treatment should not be interpreted as a personal failure.
The better interpretation is simpler: if a medication is doing part of the work of controlling a chronic condition, removing that medication may remove part of its benefit.
That is precisely why anyone starting a GLP-1 medication deserves a conversation not only about how to start it, but also about the long-term plan.
Here is the silver lining: the story does not have to be “take a drug forever or lose everything you gained.” And the data do not show that every person who stops treatment has the same outcome.
What they do show is that maintenance deserves a plan.
That is where strength training, cardiovascular fitness, daily movement, nutrition, sleep, recovery, and a supportive community matter enormously. None is a magic substitute for medical treatment. But unlike the pharmacologic effect of a medication, the skills, strength, aerobic capacity, and routines you build are things you can carry forward.
At FITNESS SF, we are not opposed to GLP-1 medications. If a medication prescribed appropriately helps you lose weight, improve your blood sugar, reduce cardiovascular risk, move with less pain, or make meaningful progress in your health, we celebrate that progress with you.
We also believe that medication and lifestyle should not be framed as opposing teams.
Our role is to provide the environment around the prescription: a place to become stronger, improve your fitness, learn sustainable habits, and build a lifestyle capable of supporting your health whether you are taking a GLP-1 medication today, tapering one with your medical team, or never taking one at all.
Use every appropriate tool available to improve your health. Just keep building the person underneath the prescription.
*The content on this blog was written with the assistance of AI and is provided for general informational purposes only. It does not constitute medical advice. No responsibility or liability is assumed for any actions taken based on the information provided.